Elicera Therapeutics (ELIC) Q2 2026 earnings summary

Executive summary

• Operating loss for Q2 2026 was SEK -6.3 million, with a net loss of SEK -6.3 million and EPS of SEK -0.12, reflecting increased R&D and operational activities compared to Q2 2025.

• For H1 2026, operating loss reached SEK -11.4 million, net loss SEK -11.3 million, and EPS SEK -0.22, showing a slight increase in losses year-over-year.

• Strong clinical progress in the CARMA study, with 91% tumor response rate and 6 of 8 patients achieving complete metabolic response.

• Successful rights issue raised SEK 54.6 million, strengthening financial position and supporting ongoing clinical programs.

• Leadership transitions include a new CEO and Chair, with continuity ensured in scientific and operational management.

Financial highlights

• Q2 2026 operating loss: SEK -6.3 million (vs. SEK -2.9 million in Q2 2025).

• H1 2026 operating loss: SEK -11.4 million (vs. SEK -11.0 million in H1 2025).

• Cash flow from operations in H1 2026: SEK -10.9 million (vs. SEK -6.7 million in H1 2025).

• EPS for H1 2026: SEK -0.22 (vs. SEK -0.25 in H1 2025).

• Rights issue provided SEK 54.6 million before costs.

Outlook and guidance

• Capital raised will fund completion of CARMA study and accelerate ELC-401 clinical preparations.

• Preparations for ELC-401 clinical trial are on track, with regulatory guidance received and process development underway.

• Ongoing recruitment for new CEO and continued focus on advancing pipeline.